Biostatistics Semaglutide s.c., Novo Nordisk A/S, Copenhagen, Denmark.
Biostatistics 1, LEO Pharma A/S, Copenhagen, Denmark.
Lifetime Data Anal. 2021 Apr;27(2):216-243. doi: 10.1007/s10985-021-09517-5. Epub 2021 Jan 30.
For equivalence trials with survival outcomes, a popular testing approach is the elegant test for equivalence of two survival functions suggested by Wellek (Biometrics 49: 877-881, 1993). This test evaluates whether or not the difference between the true survival curves is practically irrelevant by specifying an equivalence margin on the hazard ratio under the proportional hazards assumption. However, this approach is based on extrapolating the behavior of the survival curves to the whole time axis, whereas in practice survival times are only observed until the end of follow-up. We propose a modification of Welleks test that only addresses equivalence until end of follow-up and derive the large sample properties of this test. Another issue is the proportional hazards assumption which may not be realistic. If this assumption is violated, one may severely misjudge the actual treatment effect with a hazard ratio quantification and wrongly declare equivalence. We suggest a non-parametric test for assessing survival equivalence within the follow-up period. We derive the large sample properties of this test and provide an approximation to the limiting distribution under some mild assumptions on the functional form of the difference between the two survival curves. Both suggestions are investigated by simulation and applied to a clinical trial on survival of gastric cancer patients.
对于生存结局的等效性试验,一种流行的检验方法是 Wellek 提出的检验两种生存函数等效性的优雅检验(Biometrics 49: 877-881, 1993)。该检验通过在比例风险假设下指定风险比的等效边界来评估真实生存曲线之间的差异是否在实践中无关紧要。然而,这种方法基于将生存曲线的行为外推到整个时间轴,而在实践中,生存时间仅观察到随访结束。我们提出了对 Welleks 检验的一种修改,仅在随访结束时处理等效性,并推导出该检验的大样本性质。另一个问题是比例风险假设,这可能不现实。如果违反了这个假设,人们可能会严重误判实际的治疗效果,错误地宣布等效。我们建议在随访期间进行生存等效性的非参数检验。我们推导出该检验的大样本性质,并在两个生存曲线之间的差异的函数形式的一些温和假设下,提供了对极限分布的近似。这两个建议都通过模拟进行了研究,并应用于胃癌患者生存的临床试验。